ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2794

Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis

Joo Youn Lee1, Min Jueng Kang1, Ji Yong Choi2, Ji Soo Park3, Jin Kyun Park1,2, Eun Young Lee4, Eun Bong Lee5, Thomas Pap6, Eugene Yi1 and Yeong Wook Song1,2, 1Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), 3Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), 4Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 5Division of Rheumatology, Department of Internal Medicine, Seoul National University, seoul, Korea, Republic of (South), 6Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and joint destruction. Monocytes and synovial macrophages are key players in inflammatory process of RA. Enolase-1 (ENO1) is a multifunctional glycolytic enzyme in cytoplasm of cells and it is also found on the cell surface as plasminogen receptor. The majority of cells expressing ENO1 in peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) derived from RA patients were known to be CD14-positive monocytes and macrophages. This study was aimed to discover and investigate a novel ligand of cell surface expressed ENO1 and biological role of the interaction between ENO1 and its novel ligand, apolipoprotein B (apoB).

Methods: ENO1 binding protein was identified present in RA synovial fluid (SF) using affinity-base mass spectrometry analysis. The interaction between ENO1 and apoB was evaluated using physical characterization, such as ligand blotting assay, ligand binding assay, surface plasmon resonance (SPR), and confocal microscopy. The production of pro-inflammatory cytokines in PBMCs from RA or healthy control (HC) after stimulation with apoB were evaluated using cytokines ELISA. The pro-inflammatory effect of apoB was evaluated in K/BxN serum transfer arthritis mouse model.

Results: Characterization of physical interaction between ENO1 and apoB using various binding assay, ligand blotting assay, ligand binding assay, SPR, and confocal microscopy showed that apoB is a novel ligand of ENO1. Interaction between surface ENO1 and apoB induced higher levels of pro-inflammatory cytokines in RA PBMCs than HC PBMCs. When surface ENO1 expression was down-regulated after transfection with ENO1-specific siRNA, production of inflammatory cytokines by RA PBMCs in response to apoB stimulation decreased. Moreover, in K/BxN serum transfer arthritis model, mice were immunized with K/BxN serum and apoB induced exacerbation of arthritis with increased ankle thickness, arthritis score, and production of pro-inflammatory cytokines. LDLR knockout mice are known to have high levels of serum LDL and apoB. The arthritis score and ankle thickness were markedly higher in low density lipoproteins receptor (LDLR) knockout mice compared to wild type after K/BxN serum transfer.

Conclusion: In this study, we discovered apoB as a novel ligand of ENO1. ApoB may enhance chronic inflammation in RA patients.


Disclosure: J. Y. Lee, None; M. J. Kang, None; J. Y. Choi, None; J. S. Park, None; J. K. Park, None; E. Y. Lee, None; E. B. Lee, None; T. Pap, None; E. Yi, None; Y. W. Song, None.

To cite this abstract in AMA style:

Lee JY, Kang MJ, Choi JY, Park JS, Park JK, Lee EY, Lee EB, Pap T, Yi E, Song YW. Apolipoprotein B Binds to Enolase-1 and Aggravates Inflammation in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/apolipoprotein-b-binds-to-enolase-1-and-aggravates-inflammation-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apolipoprotein-b-binds-to-enolase-1-and-aggravates-inflammation-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology